Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review.

Spread the love

Review

. 2021 Jan 25.

doi: 10.1007/s11481-021-09982-7. Online ahead of print.

Affiliations

Item in Clipboard

Review

Alessia Furgiuele et al. J Neuroimmune Pharmacol. .

Abstract

Multiple sclerosis (MS) is the most common chronic autoimmune disease of the central nervous system. Efficacy of treatments for MS is associated with risk of adverse effects, and effective and well-tolerated drugs remain a major unmet need. Cannabis (Cannabis sativa L., fam. Cannabaceae) and cannabinoids are popular among MS patients to treat spasticity and pain. Cannabinoids are endowed with remarkable immunomodulating properties, and in particular the non-psychotropic cannabinoid cannabidiol (CBD) is increasingly recognized as anti-inflammatory and immunosuppressive, nevertheless with excellent tolerability even at high doses. In this systematic review, we retrieved and critically evaluated available evidence regarding the immune and disease-modifying effects of CBD in experimental autoimmune encephalomyelitis (EAE) and in MS. Evidence in rodent models of EAE strongly supports CBD as effective, while clinical evidence is still limited and usually negative, due to paucity of studies and possibly to the use of suboptimal dosing regimens. Better characterization of targets acted upon by CBD in MS should be obtained in ex vivo/in vitro studies in human immune cells, and higher doses should be tested in well-designed clinical trials with clinically relevant efficacy endpoints. Graphical Abstract.

Keywords: Cannabidiol; Experimental autoimmune encephalomyelitis; Immunomodulation; Multiple sclerosis.

References

    1. Al-Ghezi ZZ, Busbee PB, Alghetaa H, Prakash S, Nagarkatti PS, Nagarkatti M (2019a) Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav Immun 82:25–35 – PubMed PMC DOI
    1. Al-Ghezi ZZ, Miranda K, Nagarkatti M, Nagarkatti PS (2019b) Combination of cannabinoids, delta 9-tetrahydrocannabinol and cannabidiol, ameliorates experimental multiple sclerosis by suppressing neuroinflammation through regulation of miRNA-mediated signaling pathways. Front Immunol 10:1921 – PubMed PMC DOI
    1. Andre CM, Hausman J-F, Guerriero G (2016) Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci 7:19 – PubMed PMC DOI
    1. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019) Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel) 9:21 – DOI
    1. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9–13 – PubMed DOI

Publication types

Avatar

Schaka

error: Content is protected !!
%d blogueurs aiment cette page :